Right Treatment, Right Patient: Evidence-Based Approaches to the Treatment of Moderate-to-Severe Atopic Dermatitis
Snippet 1: Currently Available Injectable Biologic Therapies for Moderate-to-Severe Atopic Dermatitis (AD)
May 12, 2023
May 12, 2024
Allergy & Immunology, Dermatology, Primary Care
This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and Catamount Medical Education.
This activity is supported by an educational grant from Lilly.
- Physicians — maximum of 0.25 AMA PRA Category 1 Credit(s)™
- Nurses — 0.25 Contact Hours
- Physician Associate — maximum of 0.25 AAPA Category 1 CME Credit
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed to meet the educational needs of dermatology and allergy physicians, nurse practitioners, PAs, and nurses who care for patients with moderate-to-severe atopic dermatitis.
This activity features a case presentation, a brief overview of currently available injectable biologic therapies, and insights from an expert faculty.
After completing this activity, the participant should be better able to::
- Identify the biologic properties and mechanisms of action of current and emerging biological therapies for moderate-to-severe atopic dermatitis
- Evaluate evidence on the efficacy and safety, along with the impact on patients’ quality of life, of current and emerging biological therapies for moderate-to-severe atopic dermatitis
- Apply patient-, disease-, and therapy-specific considerations in treatment decisions for patients with moderate-to-severe atopic dermatitis
Benjamin Ungar, MD (Development and Presenting Faculty)
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York
Keri Holyoak, PA-C, MPH (Development Faculty)
Dermatology Center of Salt Lake
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Catamount Medical Education. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Physician Continuing Education
PACE designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is .25 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
PA Continuing Medical Education
PACE has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until May 12, 2024. PAs should only claim credit commensurate with the extent of their participation
All other health care professionals completing this course will be issued a statement of participation.
Disclosures of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
- Benjamin Ungar, MD
- Consulting Fees: Arcutis, Castle Biosciences, Pfizer, Sanofi
- Speaker Honoraria: Arcutis, Castle Biosciences, Pfizer, Sanofi
- Grant Funding Fee: Incyte, Pfizer, Rapt
- Keri Holyoak, PA-C, MPH
- Consulting Fees: Leo
- Speaker Honoraria: Dermavant, Galderma, Pfizer, Regeneron, Sanofi
Susan Denner, MD, MS, Medical Director, Catamount Medical Education has no relevant financial relationships to report.
Danielle Ellinas, Director of Operations, Catamount Medical Education has no relevant financial relationships to report.
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Instructions for Participation and Credit
This activity is an online enduring material. There are no fees for participating and receiving credit for this activity. During the period that the activity is available for credit, participants must:
- Read the CE information.
- Complete the pretest.
- View the content.
- Complete the posttest and the evaluation form .
A score of 100% correct must be achieved on the posttest to successfully complete the activity. If you do not receive a passing score, you will receive a message notifying you that you did not pass the posttest. You may retake the posttest until successful. Upon completion of the evaluation, your certificate will be emailed to you.
The estimated time to complete the activity is 15 minutes.
This activity was originally released on May 12, 2023, and is eligible for credit through May 12, 2024.
Course Viewing Requirements
This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser.
Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
Our Policy on Privacy
PACE and Catamount Medical Education, LLC respect your privacy. All personal information that is provided to Catamount Medical Education, LLC is protected and will not be sold to a third party for commercial purposes. All personally identifiable information contained in the Catamount Medical Education, LLC registration databases is treated as confidential and will be used only for the purposes stated in this policy, except where required by law. Catamount Medical Education, LLC maintains user databases that contain mailing and user profile information as well as a record of the CME activities viewed and the post-test and evaluation results for CME credit. This information is provided to activity collaborators for the purposes of CME recordkeeping. By participating in this activity, you agree that Catamount Medical Education, LLC has full permission to provide this information. For each visitor to this Web site, our Web server automatically recognizes information such as the visitor’s IP address. Catamount Medical Education, LLC safeguards against the loss, misuse, or alteration of information that we have collected in this activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For questions about this activity, please contact Catamount Medical Education at email@example.com.
For information about the accreditation of this activity, please visit www.partnersed.com.